FASCINATING analysis of the landscape of immuno-oncology trials, from @Annals_Oncology. h/t @nickhaining watermark.silverchair.com/mdx755.pdf?tok…
Remarkable findings: >2000 agents, >900 in clinical stage, against 300 targets, from >800 companies. 
>3000 trials with combined target accrual of over half a million (you read that right) patients.
We complain that too few (adult) #cancer patients enroll in #clinicaltrials, but maybe part of the problem is that there are too many trials?
5/ No wonder the need for & challenge of prioritization of clinical trials. From @HollyLynchez @CohenProf et al: jme.bmj.com/content/43/12/…
6/ Also striking: 251 trials of anti-PD1/L1 in combo w anti-CTLA-4; 170 trials of anti-PD1/L1 in combo w chemo. Are these the right #s? Need for coordination across landscape? Tang et al ask the right questions. /end
A point I neglected to flag: 2/3 of trials across immuno-onc landscape are investigator-initiated, often single-center and small. My prediction: relatively few will contribute meaningful knowledge.
What think you of the Tang et al immuno-oncology story, @VinayPrasad82?
